PL3273953T3 - Stabilny preparat do pozajelitowego podawania tapentadolu - Google Patents

Stabilny preparat do pozajelitowego podawania tapentadolu

Info

Publication number
PL3273953T3
PL3273953T3 PL16714327T PL16714327T PL3273953T3 PL 3273953 T3 PL3273953 T3 PL 3273953T3 PL 16714327 T PL16714327 T PL 16714327T PL 16714327 T PL16714327 T PL 16714327T PL 3273953 T3 PL3273953 T3 PL 3273953T3
Authority
PL
Poland
Prior art keywords
tapentadol
parenteral administration
stable formulation
formulation
stable
Prior art date
Application number
PL16714327T
Other languages
English (en)
Inventor
Marc Schiller
Carlos Van Hemelrijck
Stefanie Straub
Eva Cornelia WULSTEN
Ulrike Bertram
Ulrich Reinhold
Original Assignee
Grünenthal GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55661386&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL3273953(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Grünenthal GmbH filed Critical Grünenthal GmbH
Publication of PL3273953T3 publication Critical patent/PL3273953T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL16714327T 2015-03-27 2016-03-23 Stabilny preparat do pozajelitowego podawania tapentadolu PL3273953T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP15161487 2015-03-27
EP15169730 2015-05-28
PCT/EP2016/056376 WO2016156147A1 (en) 2015-03-27 2016-03-23 Stable formulation for parenteral administration of tapentadol
EP16714327.0A EP3273953B1 (en) 2015-03-27 2016-03-23 Stable formulation for parenteral administration of tapentadol

Publications (1)

Publication Number Publication Date
PL3273953T3 true PL3273953T3 (pl) 2019-07-31

Family

ID=55661386

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16714327T PL3273953T3 (pl) 2015-03-27 2016-03-23 Stabilny preparat do pozajelitowego podawania tapentadolu

Country Status (28)

Country Link
US (2) US20160279078A1 (pl)
EP (2) EP3479823B1 (pl)
JP (1) JP6923447B2 (pl)
KR (1) KR20170132282A (pl)
CN (1) CN107847471A (pl)
AU (1) AU2016239772B2 (pl)
BR (1) BR112017018569A2 (pl)
CA (1) CA2979034A1 (pl)
CL (1) CL2017002306A1 (pl)
CO (1) CO2017009400A2 (pl)
CY (1) CY1121371T1 (pl)
DK (1) DK3273953T3 (pl)
EA (1) EA036258B1 (pl)
EC (1) ECSP17064188A (pl)
ES (2) ES2710299T3 (pl)
HK (1) HK1252705A1 (pl)
HR (1) HRP20190231T1 (pl)
HU (1) HUE042612T2 (pl)
IL (1) IL254136A0 (pl)
LT (1) LT3273953T (pl)
MX (1) MX2017012312A (pl)
PE (1) PE20171651A1 (pl)
PL (1) PL3273953T3 (pl)
PT (2) PT3273953T (pl)
RS (1) RS58301B1 (pl)
SI (1) SI3273953T1 (pl)
TW (1) TW201642843A (pl)
WO (1) WO2016156147A1 (pl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX388963B (es) 2011-03-04 2025-03-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral
PE20171651A1 (es) 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol
EP3515412B1 (en) 2016-09-23 2025-04-23 Grünenthal GmbH Stable formulation for parenteral administration of tapentadol
EP3585370A1 (en) 2017-02-23 2020-01-01 Grünenthal GmbH Tapentadol as local anesthetic
CN114788814B (zh) * 2021-01-26 2023-10-13 浙江创新生物有限公司 一种高稳定性的注射用达托霉素组合物及其制备方法和其应用
IT202400002503A1 (it) * 2024-02-07 2025-08-07 S A L F S P A Laboratorio Farm Formulazione iniettabile sterile a base di rocuronio

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8334422D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
GB8334423D0 (en) 1983-12-23 1984-02-01 Sterwin Ag Composition
US4775678A (en) 1984-10-01 1988-10-04 Schering Corporation Clotrimazole cream
AU614465B2 (en) 1989-04-05 1991-08-29 Yissum Research Development Company Of The Hebrew University Of Jerusalem Medicinal emulsions
DE4426245A1 (de) 1994-07-23 1996-02-22 Gruenenthal Gmbh 1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
US6183758B1 (en) 1998-01-29 2001-02-06 Highland Laboratories, Inc. Phytochemicals, nutrients & medication absorption &/or treatment
US6211169B1 (en) 1999-09-29 2001-04-03 Aesgen, Inc. Stable calcitriol solution for packaging into vials
FR2809619B1 (fr) * 2000-06-06 2004-09-24 Pharmatop Nouvelles formulations aqueuses de principes actifs sensibles a l'oxydation et leur procede d'obtention
US6399087B1 (en) 2000-12-20 2002-06-04 Amphastar Pharmaceuticals, Inc. Propofol formulation with enhanced microbial inhibition
US20050176790A1 (en) 2001-02-28 2005-08-11 Johannes Bartholomaus Pharmaceutical salts
DE10109763A1 (de) 2001-02-28 2002-09-05 Gruenenthal Gmbh Pharmazeutische Salze
DE10112325A1 (de) 2001-03-13 2002-10-02 Fresenius Kabi De Gmbh Lagerstabile Fertiginfusionslösungen des Paracetamols
JP4905616B2 (ja) 2001-04-19 2012-03-28 ライオン株式会社 ソフトコンタクトレンズ用点眼剤
US6638981B2 (en) 2001-08-17 2003-10-28 Epicept Corporation Topical compositions and methods for treating pain
PE20030527A1 (es) 2001-10-24 2003-07-26 Gruenenthal Chemie Formulacion farmaceutica con liberacion retardada que contiene 3-(3-dimetilamino-1-etil-2-metil-propil) fenol o una sal farmaceuticamente aceptable del mismo y tabletas para administracion oral que la contienen
FR2832063B1 (fr) 2001-11-15 2004-08-27 Aguettant Lab Procede de production de solutions stables de substances phenoliques et les solutions en resultant
CA2479350A1 (en) 2002-03-15 2003-09-25 Cypress Bioscience, Inc. Ne and 5-ht reuptake inhibitors for treating visceral pain syndromes
US20030191187A1 (en) 2002-04-01 2003-10-09 Lee Fang Yu Injectable pharmaceutical composition containing a non-steroidal anti-inflammatory drug and method for preparing the same
US20040101563A1 (en) 2002-07-18 2004-05-27 Kundu Subhas C. Storage stable antihistaminic syrup formulations
RU2359698C2 (ru) 2002-09-13 2009-06-27 Сайдекс, Инк. Капсулы, содержащие водные наполняющие композиции, стабилизированные производным циклодекстрина
US6888993B2 (en) 2002-11-27 2005-05-03 Corning Incorporated Dispersion compensating optical fiber for SMF and transmission link including same
ITMI20022748A1 (it) 2002-12-23 2004-06-24 Eurand Int Dispersioni solide stabilizzate di farmaco in un carrier organico e procedimento per la loro preparazione.
DE602004019761D1 (de) 2003-01-08 2009-04-16 Novartis Vaccines & Diagnostic Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
US20040180915A1 (en) 2003-03-14 2004-09-16 Xanodyne Pharmacal, Inc. Methadone-containing compositions for parenteral administration and method of use thereof
US20060111382A1 (en) 2004-05-17 2006-05-25 Pharmacofore, Inc. Compositions and methods for treating or preventing pain
PT1612203E (pt) 2004-06-28 2007-08-20 Gruenenthal Gmbh ''formas cristalinas de cloridrato de (-) - (1r,2r) - 3 -(3-dimetilamino-l-etil - 2 - metilpropil) fenol''
BRPI0513300B1 (pt) 2004-07-01 2018-11-06 Gruenenthal Gmbh forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2- metil-lpropil)-fenol
DE102004032103A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
EP1893190A4 (en) 2005-04-28 2010-07-28 Theraquest Biosciences Llc METHODS AND COMPOSITIONS FOR TREATING PAIN
CA2618799C (en) * 2005-08-12 2013-06-04 Bharat Serums & Vaccines Ltd. Aqueous anaesthetic compositions comprising propofol
TWI329334B (en) 2005-12-02 2010-08-21 Chung Shan Inst Of Science Manufacture method of electromagnetic interference layer for the plasma display panel
US8176534B2 (en) 2005-12-30 2012-05-08 General Instrument Corporation Method and apparatus for provisioning a device to access digital rights management (DRM) services in a universal plug and play (UPnP) network
WO2007127158A2 (en) 2006-04-25 2007-11-08 Croda, Inc Modification of percutaneous absorption of topically active materials
ATE502629T1 (de) 2006-04-28 2011-04-15 Gruenenthal Gmbh Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl) phenol und einem nsar
PL2012764T3 (pl) 2006-04-28 2011-04-29 Gruenenthal Gmbh Kombinacja farmaceutyczna zawierająca 3-(3-dimetyloamino-1-etylo-2-metylopropylo)fenol i Paracetamol
BRPI0714671B8 (pt) 2006-07-24 2023-03-21 Janssen Pharmaceutica Nv Preparação de (2r,3r)-3-(3-metoxifenil)-n,n,2-trimetilpentanamina e compostos intermediários
EP1905440A1 (de) 2006-09-06 2008-04-02 Boehringer Ingelheim Pharma GmbH & Co. KG Verwendung einer pharmazeutischen Zusammensetzung enthaltend ein Anticholinergikum zur Abtötung von Mikroorganismen und zur Behandlung von Atemwegsinfektionen
TWI394564B (zh) 2006-09-21 2013-05-01 Alcon Res Ltd 自行保存型水性藥學組成物
DE102007012165A1 (de) 2007-03-12 2008-09-18 Grünenthal GmbH Verwendung von 1-Phenyl-3-dimethylamino-propanverbindungen zur Therapie des Neuropathieschmerzes
JP2008266168A (ja) 2007-04-18 2008-11-06 Teika Seiyaku Kk 眼科用剤
EP1985292A1 (en) 2007-04-23 2008-10-29 Grünenthal GmbH Titration of tapentadol
EP1992334A1 (en) 2007-05-08 2008-11-19 Docpharma NV/SA Storage-stable formulation of oxidation-sensitive phenolic drug, especially paracetamol, comprises aqueous drug solution deoxygenated by a temperature-controlled manufacturing process of the formulation
RS55769B1 (sr) 2007-11-23 2017-07-31 Gruenenthal Gmbh Kompozicije tapentadola
AU2008335360A1 (en) 2007-12-06 2009-06-18 Pain Therapeutics, Inc. Micronized opioid compositions, formulations and dosage forms and methods of making same
CA2713128C (en) 2008-01-25 2016-04-05 Gruenenthal Gmbh Pharmaceutical dosage form
EP2280688B1 (en) 2008-04-08 2012-01-25 Acino Pharma AG Aqueous pharmaceutical formulation
RU2673882C1 (ru) 2008-10-30 2018-12-03 Грюненталь Гмбх Новые и эффективные лекарственные формы тапентадола
RU2011133020A (ru) 2009-01-09 2013-02-20 Панацеа Биотек Лтд. Фармацевтические суспензии двойного высвобождения
WO2010100477A2 (en) 2009-03-03 2010-09-10 Shire Llc Amino acid and peptide carbamate prodrugs of tapentadol and uses thereof
EP2246044A1 (en) 2009-04-21 2010-11-03 Pierre Fabre Dermo-Cosmétique Paediatric solutions comprising a beta-blocker
US20100272815A1 (en) 2009-04-28 2010-10-28 Actavis Group Ptc Ehf Amorphous form of tapentadol hydrochloride
JP5615821B2 (ja) 2009-08-05 2014-10-29 ナガセ医薬品株式会社 インジゴカルミン製剤
CN102711726A (zh) * 2009-12-10 2012-10-03 特克尼梅德医疗技术股份公司 用于制备扑热息痛稳定液体制剂的方法和组合物
US20110190267A1 (en) 2010-01-05 2011-08-04 Shire Pharmaceuticals, Inc. Prodrugs of opioids and uses thereof
ES2829386T3 (es) 2010-03-30 2021-05-31 Phosphagenics Ltd Parche de administración transdérmica
GB201006200D0 (en) 2010-04-14 2010-06-02 Ayanda As Composition
US20120270848A1 (en) 2010-10-22 2012-10-25 Galleon Pharmaceuticals, Inc. Novel Compositions and Therapeutic Methods Using Same
CN103501775A (zh) * 2011-03-04 2014-01-08 格吕伦塔尔有限公司 他喷他多的胃肠外给药
ES2910085T3 (es) * 2011-03-04 2022-05-11 Gruenenthal Gmbh Composición farmacéutica acuosa semisólida que contiene tapentadol
MX388963B (es) * 2011-03-04 2025-03-20 Gruenenthal Gmbh Formulacion farmaceutica acuosa de tapentadol para administracion oral
US20150073000A1 (en) 2012-03-27 2015-03-12 Fresenius Kabi Oncology Limited Stable ready-to-use pharmaceutical composition of pemetrexed
CN103159633B (zh) 2012-07-06 2015-08-12 江苏恩华药业股份有限公司 他喷他多的制备方法及用于制备他喷他多的化合物
GB201309654D0 (en) 2013-05-30 2013-07-17 Euro Celtique Sa Method
CN103735500B (zh) 2014-01-28 2016-01-20 江苏华泽医药科技有限公司 盐酸他喷他多注射液及其制备方法
PE20171651A1 (es) 2015-03-27 2017-11-13 Gruenenthal Chemie Formulacion estable para administracion parenteral de tapentadol

Also Published As

Publication number Publication date
IL254136A0 (en) 2017-10-31
KR20170132282A (ko) 2017-12-01
PT3479823T (pt) 2020-09-29
PE20171651A1 (es) 2017-11-13
BR112017018569A2 (pt) 2018-04-24
JP6923447B2 (ja) 2021-08-18
DK3273953T3 (en) 2019-03-11
AU2016239772B2 (en) 2021-05-13
US20180125800A1 (en) 2018-05-10
HRP20190231T1 (hr) 2019-04-05
EP3273953A1 (en) 2018-01-31
JP2018509462A (ja) 2018-04-05
US20160279078A1 (en) 2016-09-29
EP3273953B1 (en) 2019-01-02
EA201792144A1 (ru) 2018-03-30
EA036258B1 (ru) 2020-10-20
ES2822113T3 (es) 2021-04-29
HK1252705A1 (zh) 2019-05-31
RS58301B1 (sr) 2019-03-29
CN107847471A (zh) 2018-03-27
MX2017012312A (es) 2018-01-18
SI3273953T1 (sl) 2019-03-29
CL2017002306A1 (es) 2018-03-23
EP3479823A1 (en) 2019-05-08
TW201642843A (zh) 2016-12-16
CA2979034A1 (en) 2016-10-06
HUE042612T2 (hu) 2019-07-29
CY1121371T1 (el) 2020-05-29
AU2016239772A1 (en) 2017-09-14
EP3479823B1 (en) 2020-09-09
CO2017009400A2 (es) 2018-01-05
US11013701B2 (en) 2021-05-25
PT3273953T (pt) 2019-04-01
LT3273953T (lt) 2019-02-25
WO2016156147A1 (en) 2016-10-06
ECSP17064188A (es) 2018-03-31
ES2710299T3 (es) 2019-04-24

Similar Documents

Publication Publication Date Title
SG10202106970XA (en) Stable anti-ifnar1 formulation
HUE059921T2 (hu) Stabil nimodipin parenterális készítmény
PT3426294T (pt) Formulação farmacêutica compreendendo anticorpo, ciclodextrina e metionina
IL254136A0 (en) Stable composition for intravenous administration of tapentadol
IL253570A0 (en) Pharmacy composition
IL253177A0 (en) Pharmacy preparation
IL266537A (en) pharmaceutical preparation
IL266755B (en) A pharmaceutical preparation for parenteral administration containing carglumic acid
HRP20181968T1 (hr) Formulacije temeljene na melatoninu za parenteralno davanje
ZA201807851B (en) Pharmaceutical formulation
SMT202000062T1 (it) Formulazione di fosfomicina per la somministrazione parenterale
GB201506755D0 (en) Novel pharmaceutical formulation
GB201511246D0 (en) Pharmaceutical formulation
IL265477A (en) Stable formulation for intravenous administration of tapentadol
IL258420A (en) Stable formulations of fingolimod
ZA201703330B (en) Process for preparation of parenteral formulation of anidulafungin
GB201402377D0 (en) Stable polymorph form B of tapentadol hydrochloride
HK40009919A (zh) 用於肠胃外施用他喷他多的稳定制剂